Ondine Biomedical treats first patients in nasal photodisinfection US Phase 2 trial for the prevention of post-operative infections Vancouver, Canada, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Post-operative infections occur in up to 300,000 patients per year in the United States and cost the US healthcare system tens of billions of...

Photodisinfection technology could be a game-changer in fight against antimicrobial resistance Vancouver, Canada, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Ondine Biomedical’s photodisinfection technology is one of the only new technologies available to economically combat drug-resistant...

Ondine Biomedical appoints Charles Young to lead sales and marketing activity in North America Vancouver, Canada, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Ondine Biomedical Inc. (LON:OBI) has appointed Charles Young as its VP Sales & Marketing, North America to lead the commercialization of its...

Ondine Biomedical appoints Professor Trevor Jones to lead COVID-19 advisory board Vancouver, Canada, Dec. 15, 2021 (GLOBE NEWSWIRE) -- AIM listed life sciences company, Ondine Biomedical, has appointed Professor Trevor Jones CBE FMedSci to lead a new advisory board on the use of...